Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

44P BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy.

Autor: O'Kane, G.M.¹ (AUTHOR), Spratlin, J.² (AUTHOR), Oh, D-Y.³ (AUTHOR), Rha, S.Y.⁴ (AUTHOR), McWhirter, E.⁵ (AUTHOR), Elimova, E.⁶ (AUTHOR), Kavan, P.⁷ (AUTHOR), Choi, M.K.⁸ (AUTHOR), Kim, D.⁹ (AUTHOR), Goodwin, R.A.¹⁰ (AUTHOR), Hecht, J.R.¹¹ (AUTHOR), Koo, D-H.¹² (AUTHOR), Halani, K.¹³ (AUTHOR), McAllister, R.¹⁴ (AUTHOR), Jones, M.¹⁴ (AUTHOR), Snow, M.D.¹⁵ (AUTHOR), Lemmerick, Y.¹⁶ (AUTHOR), Spera, G.¹⁷ (AUTHOR), Pankovich, J.¹⁵ (AUTHOR)

Publikováno v: Annals of Oncology. 2024 Supplement 1, Vol. 35, pS22-S22. 1p.